- Home
- CB vs TGTX Comparison
CB vs TGTX Comparison
Compare CB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | TGTX |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4B | 5.5B |
| IPO Year | 1993 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CB | TGTX |
|---|---|---|
| Price | $311.18 | $31.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $309.65 | $54.75 |
| AVG Volume (30 Days) | ★ 2.1M | 1.6M |
| Earning Date | 01-27-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 23.94 | 2.78 |
| Revenue | ★ $58,842,000,000.00 | $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | $5.28 | $48.75 |
| P/E Ratio | $12.98 | ★ $11.16 |
| Revenue Growth | 7.43 | ★ 100.88 |
| 52 Week Low | $252.16 | $25.28 |
| 52 Week High | $313.46 | $46.48 |
Technical Indicators
Market Signals| Indicator | CB | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 48.42 |
| Support Level | $308.50 | $29.79 |
| Resistance Level | $313.46 | $32.30 |
| Average True Range (ATR) | 4.70 | 1.09 |
| MACD | 0.60 | 0.03 |
| Stochastic Oscillator | 87.69 | 61.38 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.